首页> 外国专利> Assay for distinguishing between sepsis and systemic inflammatory response syndrome

Assay for distinguishing between sepsis and systemic inflammatory response syndrome

机译:区分败血症和全身性炎症反应综合征的方法

摘要

There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no increase is observed in the one or more biomarker for SIRS, in the sample obtained from the patient relative to the corresponding reference value; and wherein the patient is diagnosed as having SIRS, when an increase is observed in the one or more biomarker for SIRS, and no increase is observed in the one or more biomarker for sepsis, in the sample obtained from the patient relative to the corresponding reference value.
机译:提供了一种在患者中区分败血症和全身性炎症反应综合征(SIRS)的方法,其包括:(i)确定从脓毒症获得的样品中一种或多种脓毒症生物标志物和一种或多种SIRS生物标志物的量。患者,其中一种或多种败血症生物标志物选自:ITGB3,ITGA2B,MYL9,LCN2,TREML1,LCN15,CMTM5,PPBP和PF4;且SIRS的一种或多种生物标志物选自:PLA2G7,ARHGEF10L,MYCL,TGFBI和GPR124,(ii)比较(i)中所述样品中确定的败血症的一种或多种生物标志物的量,代表健康个体的相应参考值,(iii)将在(i)中所述样品中确定的一种或多种SIRS生物标记物的量与代表健康个体的相应参考值进行比较;其中,从患者获得的样品中,相对于相应的参考值,当观察到一种或多种脓毒症生物标志物升高而未观察到SIRS的一种或多种生物标志物升高时,该患者被诊断为患有败血症;并且其中当从患者获得的样品中相对于相应的参考而言,当在一种或多种SIRS生物标志物中观察到升高,而在一种或多种败血症生物标志中未观察到升高时,将患者诊断为患有SIRS。值。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号